DATSCAN Drug Patent Profile
✉ Email this page to a colleague
When do Datscan patents expire, and what generic alternatives are available?
Datscan is a drug marketed by Ge Hlthcare Inc and is included in one NDA.
The generic ingredient in DATSCAN is ioflupane i-123. Two suppliers are listed for this compound. Additional details are available on the ioflupane i-123 profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Datscan
A generic version of DATSCAN was approved as ioflupane i-123 by CURIUM on March 30th, 2022.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DATSCAN?
- What are the global sales for DATSCAN?
- What is Average Wholesale Price for DATSCAN?
Summary for DATSCAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 7 |
| Clinical Trials: | 17 |
| Patent Applications: | 102 |
| What excipients (inactive ingredients) are in DATSCAN? | DATSCAN excipients list |
| DailyMed Link: | DATSCAN at DailyMed |
Recent Clinical Trials for DATSCAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Invicro | Phase 1 |
| GE Healthcare | Phase 1 |
| PPD | Phase 1 |
Pharmacology for DATSCAN
| Drug Class | Radioactive Diagnostic Agent |
| Mechanism of Action | Radiopharmaceutical Activity |
US Patents and Regulatory Information for DATSCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Hlthcare Inc | DATSCAN | ioflupane i-123 | SOLUTION;INTRAVENOUS | 022454-001 | Jan 14, 2011 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DATSCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Hlthcare Inc | DATSCAN | ioflupane i-123 | SOLUTION;INTRAVENOUS | 022454-001 | Jan 14, 2011 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DATSCAN
See the table below for patents covering DATSCAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Netherlands | 300123 | ⤷ Sign Up | |
| European Patent Office | 0831941 | NEUROSONDES IODEES POUR CARTOGRAPHIER LES SITES DE REABSORPTION DE LA MONOAMINE (IODINATED NEUROPROBES FOR MAPPING MONOAMINE REUPTAKE SITES) | ⤷ Sign Up |
| Germany | 69332544 | ⤷ Sign Up | |
| Spain | 2385202 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for DATSCAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0703791 | 300123 | Netherlands | ⤷ Sign Up | |
| 0703791 | 03C0021 | France | ⤷ Sign Up | PRODUCT NAME: IOFLUPANE (123 I); REGISTRATION NO/DATE: EU/1/00/135/001 20000727 |
| 0703791 | C300123 | Netherlands | ⤷ Sign Up | PRODUCT NAME: IOFLUPANE (123I); NAT. REGISTRATION NO/DATE: EU/1/00/135/001 20000727; FIRST REGISTRATION: EU/1/00/135/001 20000727 |
| 0703791 | CA 2003 00010 | Denmark | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
